pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
France, LYON HQ
363 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 66
- Patents
- 0
Fexofenadine HCL and pseudoephedrine HCL
Approved · small molecule · Rhinitis Allergic
Fexofenadine HCL and pseudoephedrine HCL for Rhinitis Allergic is a Approved program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code LPS17348
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Rhinitis Allergic
- Status
- completed
- Trials
- 1